Prelude Therapeutics Incorporated (PRLD)
Nasdaq: PRLD · Pharmaceutical Preparations · Wilmington, DE · filing with the SEC since 2016
Income statement, as filed
In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
| Report filed | Mar 10, 2026 | Mar 10, 2025 | Feb 15, 2024 | Mar 15, 2023 | Mar 17, 2022 | Mar 16, 2021 | · |
| Revenue | 12,140 | 7,000 | · | · | · | · | · |
| Research and development | 94,300 | 117,995 | 103,393 | 92,889 | 86,778 | 48,177 | 24,279 |
| General and administrative | 22,406 | 28,719 | 28,884 | 30,651 | 26,957 | 10,586 | 3,830 |
| Total operating expenses | 116,706 | 146,714 | 132,277 | 123,540 | 113,735 | 58,763 | 28,109 |
| Operating income | -104,566 | -139,714 | -132,277 | -123,540 | -113,735 | -58,763 | -28,109 |
| Other income (expense), net | 5,068 | 12,541 | 10,445 | 8,102 | 2,041 | 1,834 | 539 |
| Income tax expense | 0 | 0 | · | · | · | · | · |
| Net income including non-controlling interests | -99,498 | -127,173 | -121,832 | -115,438 | -111,694 | -56,929 | -27,570 |
| Net income | -99,498 | -127,173 | -121,832 | -115,438 | -111,694 | -56,929 | -27,570 |
| Earnings per share, basic | -1.29 | -1.68 | -2.02 | -2.44 | -2.43 | · | · |
| Earnings per share, diluted | -1.29 | -1.68 | -2.02 | -2.44 | -2.43 | · | · |
| Earnings per share, basic and diluted | · | · | · | · | -2.43 | -4.56 | -16.52 |
| Weighted average shares, basic | 76,956,194 | 75,805,840 | 60,357,052 | 47,371,589 | 46,049,763 | · | · |
| Weighted average shares, diluted | 76,956,194 | 75,805,840 | 60,357,052 | 47,371,589 | 46,049,763 | · | · |
| Weighted average shares, basic and diluted | · | · | · | · | 46,049,763 | 12,478,463 | 1,668,549 |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it sold
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTaxResearch and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossOther income (expense), net gains and costs outside the business
us-gaap:OtherNonoperatingIncomeExpenseIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitNet income including non-controlling interests the whole group's profit, minority holders' share included
us-gaap:ProfitLossNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedEarnings per share, basic and diluted net income per share, where both counts are the same
us-gaap:EarningsPerShareBasicAndDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstandingWeighted average shares, basic and diluted the average count, where both counts are the same
us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted